Myles is active in the biotechnology, medical device and healthcare services sectors. He has led financings at six CHL portfolio companies.

Prior to joining CHL Medical Partners in 2004, Myles was a Senior Principal at Pappas Ventures where he served on the Board of a number of companies including: Angiomics, Inc. (acquired by PDL BioPharma Inc.), FlowCardia, Inc. (acquired by CR Bard), LipoScience Inc., NuVasive, Inc. (Nasdaq: NUVA), and Syntonix (acquired by Biogen Idec).

Myles is a graduate of the University of Pennsylvania School of Engineering and Applied Science, Yale University School of Medicine and Harvard Business School and is a diplomate of the American Board of Emergency Medicine. Earlier in his career he was Assistant Clinical Director of the Emergency Department at Beth Israel Deaconess Medical Center/Harvard Medical School in Boston.

Myles can be reached at mgreenberg@chlmedical.com.


Millennium Pharmacy Systems, Inc.
Oriel Therapeutics, Inc. (acquired by Novartis / Sandoz)
Still River Systems, Inc.
Vascular Pathways
Vertos Medical, Inc.